EarlyCDT® Test

lung cancer test

Oncimmune’s proprietary EarlyCDT® cancer detection tests are based on the presence in the blood of autoantibodies against specific tumour associated antigens that have the potential to detect cancer up to four years earlier than other methods and can be applied to very wide range of solid tumour types.

When a tumour is present, it produces abnormal proteins (known as antigens). Cancer antigens are different to normal antigens so the body reacts to these antigens by producing autoantibodies. These autoantibodies, which can arise in the earliest stages of cancer and have been shown to be present at all stages, are produced in sufficient quantities to be measured in an individual's blood using a simple blood test.

Oncimmune’s EarlyCDT®-Lung test has undergone extensive scientific and clinical validation studies. More than 120,000 patient samples were run to validate its technical and clinical performance to 2012. Since then over 145,000 commercial tests have also been run.

EarlyCDT®-Lung is being used in what is generally acknowledged to be the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers.